The highs and lows of venetoclax with hypomethylating agents for refractory AML

被引：0
|
作者：
Brunner, Andrew M. [1 ]
机构：
[1] Massachusetts Gen Hosp, Zero Emerson Pl,Suite 118, Boston, MA 02114 USA
来源：
LEUKEMIA RESEARCH | 2020年 / 91卷
关键词：
Acute myeloid leukemia; Venetoclax; Azacitidine; Decitabine;
D O I：
10.1016/j.leukres.2020.106320
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Highs and Lows
    Mohlenbrock, Robert H.
    NATURAL HISTORY, 2015, 123 (09) : 38 - 39
  • [32] Highs and lows?
    Bowler, Sue
    ASTRONOMY & GEOPHYSICS, 2009, 50 (04) : 4 - 4
  • [33] Highs and lows
    Rachel Jones
    Nature Reviews Neuroscience, 2001, 2 : 380 - 380
  • [34] Highs and Lows
    Durkin, Claire
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2024, 332 (12): : 965 - 966
  • [35] Hypomethylating Agents and Venetoclax in Acute Myeloid Leukemia
    DiNardo, Courtney D.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (02) : 82 - 83
  • [36] Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML
    Shimony, Shai
    Bewersdorf, Jan Philipp
    Shallis, Rory M.
    Liu, Yiwen
    Schaefer, Eva J.
    Zeidan, Amer M.
    Goldberg, Aaron D.
    Stein, Eytan M.
    Marcucci, Guido
    Lindsley, R. Coleman
    Chen, Evan C.
    Perez, Jorge Ramos
    Stein, Anthony
    DeAngelo, Daniel J.
    Neuberg, Donna S.
    Stone, Richard M.
    Ball, Brian
    Stahl, Maximilian
    LEUKEMIA, 2024, 38 (04) : 762 - 768
  • [37] Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML
    Bewersdorf, Jan Philipp
    Shimony, Shai
    Shallis, Rory M.
    Liu, Yiwen
    Berton, Guillaume
    Schaefer, Eva J.
    Zeidan, Amer M.
    Goldberg, Aaron D.
    Stein, Eytan M.
    Marcucci, Guido
    Bystrom, Rebecca P.
    Lindsley, R. Coleman
    Chen, Evan C.
    Perez, Jorge Ramos
    Stein, Anthony
    Pullarkat, Vinod
    Aldoss, Ibrahim
    DeAngelo, Daniel J.
    Neuberg, Donna S.
    Stone, Richard M.
    Garciaz, Sylvain
    Ball, Brian
    Stahl, Maximilian
    BLOOD ADVANCES, 2024, 8 (18) : 4845 - 4855
  • [38] Outcomes of Therapy with Venetoclax Combined with Hypomethylating Agents in Favorable-Risk Acute Myeloid Leukemia (AML)
    Arslan, Shukaib
    Zhang, Jianying
    Dhakal, Prajwal
    Moran, Jenna A.
    Naidoo, Nuthana
    Story, Jennifer Lombardi
    Pullarkat, Vinod A.
    Stein, Anthony S.
    Marcucci, Guido
    Yaghmour, George
    Bhatt, Vijaya R.
    Fathi, Amir T.
    Aldoss, Ibrahim
    BLOOD, 2020, 136
  • [39] Venetoclax in Combination with Hypomethylating Agents Compared to Standard Chemotherapy in Relapsed/ Refractory Acute Myeloid Leukemia
    Mohassel, Leila
    Yakubi, Hanna
    Jones, Kendra
    Wang, Hongkun
    Shafer, Danielle
    BLOOD, 2022, 140 : 6158 - 6159
  • [40] Clinical outcomes of patients receiving venetoclax and hypomethylating agents for AML in academic and academic-community partnerships
    Pham, Natalie
    Lantz, Jeffrey
    Jones, Caroline
    Kundu, Debamita
    McCann, Nicholas
    El Chaer, Firas
    Reed, Daniel
    Keng, Michael Kenneth
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345